Authors Reply to Letter to the Editor- In Response to: Comment on Durrani et al.'s "Adalimumab for Ocular Inflammation"

Ocul Immunol Inflamm. 2019;27(1):71. doi: 10.1080/09273948.2017.1379545. Epub 2017 Oct 18.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adalimumab
  • Humans
  • Inflammation*

Substances

  • Adalimumab